SEC 13F Intelligence

Managers / Q3 2020 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$338M
Q3 2020
Positions
60
Filings on Record
24
2019–present window
Filed
Nov 16, 2020
original filing

Summary

Endurant Capital Management LP reported $338M in U.S.-listed holdings across 60 positions for Q3 2020.

Its largest position, BMY, represents 7.0% of the portfolio.

Compared with Q2 2020, the fund opened 26 new positions and exited 22.

Portfolio Metrics

Turnover
+15.5%
vs prior filed quarter
Top-10 Concentration
+43.0%
share of reported value
Largest Position
+7.0%
Bristol Myers Squibb
New / Exited
26 / 22
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 69.1%Other: 14.9%ETP: 14.4%ADR: 1.4%US DOMESTIC: 0.2%
  • Common Stock · 69.1% · $234M
  • Other · 14.9% · $50M
  • ETP · 14.4% · $49M
  • ADR · 1.4% · $5M
  • US DOMESTIC · 0.2% · $682,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IARTINTEGRA LIFESCIENCES HLDGS CNEW+281.6K281.6K+$13M$13M
ISHARES TRNEW+80.5K80.5K+$12M$12M
CNMDCONMED CORPNEW+81.2K81.2K+$6M$6M
KIDSORTHOPEDIATRICS CORPNEW+126.8K126.8K+$6M$6M
SPDR SER TRNEW+52.0K52.0K+$6M$6M
PDCOEURPATTERSON COS INCNEW+163.4K163.4K+$4M$4M
VAPOTHERM INCNEW+125.7K125.7K+$4M$4M
PETSPETMED EXPRESS INCNEW+105.9K105.9K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2020

47 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM6.96%$24M390.2K
2OXFORD IMMUNOTEC GLOBAL PLCORD SHS6.07%$21M1.75M
3EHCENCOMPASS HEALTH CORPhistory →COM5.31%$18M276.1K
4ABBVABBVIE INChistory →COM5.15%$17M198.9K
5IARTINTEGRA LIFESCIENCES HLDGS Chistory →COM NEW3.93%$13M281.6K
6CICIGNA CORP NEWhistory →COM3.38%$11M67.5K
7AHCOADAPTHEALTH CORPhistory →COM CL A3.34%$11M518.4K
8JNJJOHNSON & JOHNSONhistory →COM3.30%$11M75.0K
9SIBNSI BONE INChistory →COM3.25%$11M463.1K
10ZTSZOETIS INChistory →CL A2.30%$8M47.0K
11ZBHZIMMER BIOMET HOLDINGS INChistory →COM2.18%$7M54.2K
12CNMDCONMED CORPhistory →COM1.89%$6M81.2K
13OCULOCULAR THERAPEUTIX INChistory →COM1.88%$6M837.1K
14MCKMCKESSON CORPhistory →COM1.78%$6M40.4K
158INSYNEOS HEALTH INChistory →CL A1.76%$6M112.2K
16KIDSORTHOPEDIATRICS CORPhistory →COM1.72%$6M126.8K
17TREURTRILLIUM THERAPEUTICS INChistory →COM NEW1.56%$5M372.4K
18ESPRESPERION THERAPEUTICS INC NEhistory →COM1.49%$5M135.9K
19ELVANTHEM INChistory →COM1.42%$5M17.9K
20SUTRO BIOPHARMA INCCOM1.37%$5M462.2K
21IM8NINSMED INChistory →COM PAR $.011.37%$5M144.3K
22MOLECULAR TEMPLATES INCCOM1.37%$5M422.8K
23ADAPYADAPTIMMUNE THERAPEUTICS PLChistory →SPONDS ADR1.36%$5M574.5K
24MBIOUSDMUSTANG BIO INChistory →COM1.33%$4M1.42M
25CNCCENTENE CORP DELhistory →COM1.28%$4M74.4K
26PDCOEURPATTERSON COS INChistory →COM1.16%$4M163.4K
27SELECTA BIOSCIENCES INCCOM1.11%$4M1.51M
28ACRSACLARIS THERAPEUTICS INChistory →COM1.09%$4M1.43M
29VAPOTHERM INCCOM1.08%$4M125.7K
30HAEHAEMONETICS CORPhistory →COM1.07%$4M41.6K
31PETSPETMED EXPRESS INCCOM0.99%$3M105.9K
32DGXQUEST DIAGNOSTICS INCCOM0.98%$3M29.0K
33CALLIDITAS THERAPEUTICS ABSPONSERED ADS0.79%$3M111.5K
34PROTHENA CORP PLCSHS0.78%$3M262.8K
35MGNXMACROGENICS INCCOM0.73%$2M97.4K
36TRANSLATE BIO INCCOM0.71%$2M176.7K
37FATEFATE THERAPEUTICS INCCOM0.66%$2M56.2K
38ALCON AGORD SHS0.65%$2M38.4K
39APTOSE BIOSCIENCES INCCOM NEW0.61%$2M345.2K
40VTLUSDIMMUNIC INCCOM0.61%$2M110.9K
41BUWABIO RAD LABS INCCL A0.60%$2M3.9K
42FPRXFIVE PRIME THERAPEUTICS INCCOM0.59%$2M421.4K
43KINIKSA PHARMACEUTICALS LTDCOM CL A0.53%$2M117.5K
44TRLDAVITA INCCOM0.53%$2M21.0K
45LUMINEX CORP DELCOM0.53%$2M68.1K
46BDQMALBIREO PHARMA INCCOM0.51%$2M52.1K
47ARCTARCTURUS THERAPEUTICS HLDGSCOM0.44%$1M34.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.